Innodata’s stock has garnered fresh attention following a recent increase in the consensus analyst price target from $78 to $86. This change reflects a higher valuation outlook for the company.

Medpace Holdings has recently seen its consensus analyst price target rise from $456 to approximately $519. This reflects a higher estimated fair value as sentiment improves across the contract ...

Job figures are set to take centre stage as economists continue to mull whether borrowers have seen their last Reserve Bank ...